Compare BioNano Genomics Inc (BNGO) vs Atlassian Corporation PLC (TEAM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Atlassian Corporation PLC — how do they compare? BioNano Genomics Inc trades at $1.19 (market cap $13.66M), while Atlassian Corporation PLC trades at $152.87 (market cap $39.10B). The key difference: Atlassian Corporation PLC is far larger — about 2862.4× BioNano Genomics Inc's market cap, and Atlassian Corporation PLC is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | TEAM | |
|---|---|---|
Market Cap | $13.66M | $39.10B |
Sector | Health | Technology |
52-Week High | $4.92 | $182.36 |
52-Week Low | $1.06 | $57.15 |
Enterprise Value | $16.26M | $39.09B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.16 with a bullish technical signal supported by moving averages. The company shows improving financial trends with narrowing losses and consistent earnings beats, though it remains unprofitable with negative margins. Recent news highlights operational progress including debt retirement and scientific publications. Valuation ratios appear attractive with P/S of 0.31 and P/B of 0.36.
The outlook remains speculative given persistent losses, but improving cash flow trends and analyst optimism provide catalysts. Key risks include ongoing negative profitability and competitive pressures in genomics. With 57% analyst buy ratings and bullish technical momentum, the stock offers high-risk growth potential for investors comfortable with biotech volatility.
Atlassian (TEAM) stock trades at $151.87, up 1.88% today and near its 52-week high, reflecting strong momentum after a 35% surge post-Q4 earnings. The company reported 28% revenue growth to $1.77 billion, beating estimates, with cloud revenue accelerating to 31%. Technical indicators show bullish moving averages but overbought RSI levels, while fundamentals highlight robust growth amid negative net margins. Analyst sentiment is overwhelmingly positive, with 67% buy ratings and a $161.93 consensus target.
Outlook remains favorable driven by enterprise deal expansion and AI platform adoption, though risks include high valuation multiples (P/S 6.1, EV/EBITDA 184.26) and persistent net losses. Investors should weigh growth prospects against profitability challenges and market volatility. The stock's proximity to all-time highs suggests cautious optimism is warranted.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Atlassian Corporation PLC
Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions. The company operates in four segments: subscriptions (term licenses and cloud agreements), maintenance (annual maintenance contracts that provide support and periodic updates and are generally attached to perpetual license sales), perpetual license (upfront sale for indefinite usage of the software), and other (training, strategic consulting, and revenue from the Atlassian Marketplace app store). Atlassian was founded in 2002 and is headquartered in Sydney.
Read more on TEAM →
